Romanian Journal of Pediatrics Logo
  • Home
  • Aims & Scope
  • Standards
    • Editorial policies
    • Instructions for authors
    • Peer review process
    • Guidelines for Reviewers
    • Ethics and Malpractice policies
    • Official Journal’s protocols & statements
    • Open Access
    • Fees
  • Editorial Council
  • Peer Review Council
  • EMC | CME
  • How to
  • SUBSCRIBE
  • Menu

Arhiva autor

  • About
  • Latest Posts

Maria Magdalena Florea

Latest posts by Maria Magdalena Florea (see all)

  • Pathogenic pathways of drug therapy in child’s asthma - 04/08/2015
  • BAZELE PATOGENICE ALE TRATAMENTULUI MEDICAMENTOS IN ASTMUL BRONSIC LA COPIL - 04/08/2015

Articole semnate de acelasi autor in Revista Romana de Pediatrie:

Pathogenic pathways of drug therapy in child’s asthma

SELECT ISSUE

Revista Romana de PEDIATRIE | Volumul LX, Nr. 2, An 2011
ISSN 1454-0398  |  e-ISSN 2069-6175
ISSN-L 1454-0398
DOI: 10.37897/RJP

Indexed

DOI - Crossref
Similarity Check by iThenticate, worldwide No 1 professional plagiarism checking system
DOAJ
Scopus
NLM Catalog
Ebsco Host - Medline
Google Academic
Semantic Scholar

HIGHLIGHTS

National Awards “Science and Research”

NEW! RJP has announced the annually National Award for "Science and Research" for the best scientific articles published throughout the year in the official journal.

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

Pathogenic pathways of drug therapy in child’s asthma

Maria Magdalena Florea and Stela Gotia

ABSTRACT

Asthmatic airways inflammation with still unknown various pathways involves multiple components and is orchestrated by numerous cell types, particularly mast cell, eosinophils, and CD4+ lymphocytes, but also airway structural cells. By there activation release over 100 pro-inflammatory mediators and cytokines, which in turn cause vascular leakage, bronchial smooth muscle contraction, inflammatory cell infiltration, mucus hypersecretion, airway hyper-responsiveness (AHR), and not ultimately airway remodeling. These changes are expressed clinically as recurrent wheezing, dyspnea, chest tightness and cough, which are typically associated with reversible airflow obstruction. Inhaled corticosteroids (ICS) are recommended as first-line treatment of persistent disease, but not all patients achieve asthma control even with high doses ICS or in combination with other medications, including a long acting β2 agonist or a leukotriene modifier. Such patients may require additional therapy. Last years, as we progress in knowledge asthma physiopathology, several novel anti-inflammatory therapies are in different stages of clinical development. The most clinically advanced of these is Omalizumabul (IgE antibody). Other key therapies options in clinical development either target pro-inflammatory cytokines or inflammatory cells.

Key words: allergic inflammation, asthma, anti-inflammatory treatment, biological alternative therapy

Full text | PDF

Maria Magdalena Florea

BAZELE PATOGENICE ALE TRATAMENTULUI MEDICAMENTOS IN ASTMUL BRONSIC LA COPIL

SELECT ISSUE

Revista Romana de PEDIATRIE | Volumul LX, Nr. 2, An 2011
ISSN 1454-0398  |  e-ISSN 2069-6175
ISSN-L 1454-0398
DOI: 10.37897/RJP

Indexed

DOI - Crossref
Similarity Check by iThenticate, worldwide No 1 professional plagiarism checking system
DOAJ
Scopus
NLM Catalog
Ebsco Host - Medline
Google Academic
Semantic Scholar

HIGHLIGHTS

National Awards “Science and Research”

NEW! RJP has announced the annually National Award for "Science and Research" for the best scientific articles published throughout the year in the official journal.

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

BAZELE PATOGENICE ALE TRATAMENTULUI MEDICAMENTOS IN ASTMUL BRONSIC LA COPIL

Maria Magdalena Florea and Stela Gotia

REZUMAT

Inflamaţia cronică caracteristică astmului bronşic implică multiple componenete şi este orchestrată de numeroase tipuri celulare, în mod particular de mastocite, eozinofile şi limfocitele CD4+, dar şi de celulele structurale ale căilor respiratorii. Activarea acestor celule conduce la eliberarea a peste 100 de mediatori proinflamatori şi citokine, care determină edem, bronhoconstricţie, infiltrare celulară, hipersecreţie de mucus, hiper-reactivitate bronşică (HRB) şi, nu în ultimul rând, remodelarea bronşică. Aceste modificări se exprimă clinic prin wheezing, dispnee şi tuse şi se asociază în mod caracteristic cu obstrucţia reversibilă a căilor respiratorii. Controlul inflamaţiei alergice în astm se obţine folosind corticosteroizi inhalatori (CSI) ca primă linie terapeutică, dar nu toţi pacienţii răspund, chiar şi atunci când sunt folosiţi în doze mari sau în combinaţie cu alte medicamente, inclusiv β2 agonişti cu durată lungă de acţiune şi/sau antileucotriene. Astfel de pacienţi au nevoie de terapie adiţională. În ultimii ani, pe măsură ce s-a înaintat în cunoaşterea patogeniei astmului, s-au dezvoltat câteva noi terapii antiinflamatorii, cea mai avansată fiind terapia cu Omalizumab (anticorpi antiIgE). Alte opţiuni terapeutice au ca target citokinele pro-inflamatorii sau celulele inflamatorii.

Cuvinte cheie: inflamaţie alergică, astm, tratament anti-inflamator, terapii biologice alternative

Full text | PDF

Maria Magdalena Florea


SEARCH

STANDARDE

  • Instructions for authors
  • Peer review process

Submit article

Submit your article to the journal by using the form here:

Submit

Subscriptions

To receive the Ro Journal of PEDIATRICS click here:

SUBSCRIBE
Publicare-RRPedia
Abonare_RRPedia

Partners

Partners logo

plic-maileditor@rjp.com.ro

Subscribe to the Newsletter

Articles from the journal are licensed under a 
Creative Commons Attribution 4.0 International License

 Terms & Conditions

Open Access Statement

Publisher : AMALTEA Medical Publishing House

The intended audience of the site content is professionals from the medical and pharmaceutical community.
This site does not collect any personal data nor does it use cookies that might obtain such data from your browser. [ info ]
Agree
Contact

Submit ARTICLE
E-mail: editor@rjp.com.ro  |  Mobile: +4 0742.155.512, M-F 09.00-18.00 EET

SUBSCRIPTIONS
E-mail: info@amaltea.ro |  Mobile: +4 0742.155.511, M-F 09.00-18.00 EET